Healthcare
Live Price
Offline$8.98
-0.55% today
1Y Change
-45.76%
Window
Jun 20, 2025 → Jun 1, 2026
Coverage: 237 bars · Jun 20, 2025 → Jun 1, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sysmex Corporation (SSMXY) is a Healthcare stock with a market cap of $829.76B and listed on OTC. The stock last traded around $8.98 and down 45.8% across the available one-year price window (Jun 20, 2025 → Jun 1, 2026). Baseline metrics include revenue growth of +10.2%, EPS growth of +8.6%, a dividend yield of 2.9%. What stands out right now is revenue +10.2%, EPS +8.6%, free cash flow +179.2% with operating margin 14.0% and ROIC 8.1%. The dividend matters to the case here, with a current yield around 2.9%. Valuation is more restrained than many high-expectation growth names at P/E 18.5 and price/sales 1.6. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines SSMXY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SSMXY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SSMXY Max Drawdown
-53.33%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SSMXY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$305.1B
-16.1% YoY
FY Net Income
$31.9B
-27.6% YoY
Free Cash Flow
$29.0B
+16.8% YoY
Revenue Growth
+10.2%
EPS Growth
+8.6%
Gross Margin
51.9%
Net Margin
8.9%
Income statement
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 508.6B | 461.5B | 410.5B | 363.8B | 305.1B |
| Gross Profit | 272.0B | 242.5B | 216.1B | 190.6B | 154.3B |
| Operating Income | 87.6B | 78.4B | 72.7B | 69.6B | 50.9B |
| EBITDA | 121.8B | 112.9B | 102.1B | 96.4B | 77.2B |
| Net Income | 53.7B | 49.6B | 45.8B | 44.1B | 31.9B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 89.6B | 75.5B | 69.5B | 73.8B | 66.5B |
| Total Assets | 665.3B | 618.9B | 531.1B | 483.7B | 424.9B |
| Total Liabilities | 200.7B | 186.0B | 142.7B | 134.9B | 119.0B |
| Shareholder Equity | 463.8B | 432.0B | 387.7B | 348.3B | 307.9B |
| Total Debt | 64.7B | 55.3B | 22.6B | 22.3B | 22.0B |
| Net Debt | -24.8B | -20.2B | -46.9B | -51.5B | -44.5B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
56.9B
-3.2% YoY
Capital Expenditures
27.9B
+17.8% YoY
Free Cash Flow
29.0B
+16.8% YoY
Key ratios
Gross Margin
51.9%
Operating Margin
14.0%
Net Margin
8.9%
ROE
9.4%
Debt / Equity
0.14x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.